In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?
If you prefer a monitoring strategy, how frequently do you repeat labs, and what are your referral thresholds to hepatology if you're practicing in primary care?
Specifically with GLP1-RA as seen in Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Community PollStarted
What is your first step in management for patients with a new diagnosis of MASLD?
125 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Hepatology · UCLA
Answered on · Updated on
In 2025, we should be assessing if patients are developing F2-F3 fibrosis especially with the use of non-invasive assessments (FIB-4 score, transient elastography, or MRI elastography), and then offering either Semaglutide or Resmetirom for these individuals w/ F2-F3, which are the only FDA approved...
Join for free or sign in to see the full answer
Mednet Member
Endocrinology · Uchealth Endocrinology Clinic Steamboat Springs
Answered on
The following drugs are approved for MASH:
- Semaglutide
- Liraglutide
- Thiazolidinediones (Pioglitazone, Rosiglitazone)
Join for free or sign in to see the full answer